Two Stocks Ready To Run Could Go Even Higher On Short Squeeze
April 03 2019 - 3:29PM
InvestorsHub NewsWire
Two Stocks Ready To Run Could Go
Even Higher On Short Squeeze
New York, NY -- April 3, 2019 --
InvestorsHub NewsWire -- www.nextbigticker.com -- Alternet Systems, Inc.
(USOTC:
ALYI) and Kali-Extracts, Inc. (USOTC:
KALY) both came out with strong business plan supporting news
yesterday and both had a jump in average trading volume.
Today, both are pushing past Moving Average prices and seeing MACD
crosses in spite of large market maker offers that runaway when
charged. Yesterday, the short sales reported by FINRA
exceeded 60% of total volume on both ALYI and
KALY.
![](https://static1.squarespace.com/static/5652445be4b08f0af89331fc/t/5ca4fd58e2c483930d96a747/1554316637452/Screen+Shot+2019-04-03+at+1.36.49+PM.png?format=500w)
ALYI yesterday announced a potential
$20 million order for the company’s electric
motorcycles that could result from a series of strategic meetings
next week. The stock is reacting bullishly and now the short
squeeze could add to PPS
appreciation.
ALYI is trading way above its $0.014 200
DAY MA and on the verge of breaking through its $0.029 50 DAY
MA. The MACD is on its way to a cross and the Candlestick
Pattern is Bullish Harami.
ALYI has a 52-Week High of over $0.06 and
an analyst recommended Target PPS of $0.09. Momentum today that sees a
close above $0.029 can take this stock to the next level all the
way back to its $0.06 52-Week High with a potential upside to the
$0.09 Target PPS.
![](https://static1.squarespace.com/static/5652445be4b08f0af89331fc/t/5ca4fd18e2c483930d96a463/1554316619145/Screen+Shot+2019-04-03+at+1.35.49+PM.png?format=500w)
KALY revealed yesterday for the first time
ongoing patented cannabis extract Type 2 Diabetes Treatment research the company
had previously kept under wraps adding to the recently published
research results from the company’s pilot Chronic Obstructive Pulmonary Disease (COPD)
treatment evaluation. The press release yesterday indicated two
more cannabis extract health issue treatments are also soon to be
revealed. KALY trading has shot to the OTC top 25 most
actively traded list with the PPS edging toward a breakout.
The PPS is above the 200 Day MA and has now broken past the 50 Day
MA following a MACD cross. The candlestick analysis is
indicating VERY BULLISH and now the short squeeze could add
to PPS appreciation.
KALY Potential PPS Run From $0.01 to $0.04
On Way To $0.10
KALY has the potential to run from its
$0.01 PPS level to $0.10 in the near term. Shortly after the 2018
Q4 acquisition of the patented cannabis extraction process, the
company PPS shot from sub-penny land to almost $0.04 on volume that
put it in the top 20 most actively traded stocks on the OTC Market.
The PPS retraced back to $0.01 and has been holding that price with
a healthy trading volume. With KALY’s patented cannabis
pharmaceutical research now coming to light, the PPS is positioned
to shoot past the recent $0.04 highs to a level putting it on par
with some of the other penny cannabis stock contenders. A
$0.10 PPS is a reasonable milestone following the company filing
its upcoming annual reported expected to include the company
posting its first revenue derived from its cannabis extraction
process. The company filed an extension on the 2018 annual report
with the report itself now expected within the next 15
days.
KALY is providing CBD extracts for over $1
million worth of CBD infused water produced by Puration, Inc.
(USOTC:
PURA), and KALY has also introduced its own CBD infused
gum. KALY is also implementing an extraction lab to process
biomass from Nouveau’s (USOTC:
NOUV) 100 acer hemp farm.
Following the acquisition of the patented
cannabis extraction process late last year and the corresponding
jump in price and trading volume, the OTC Markets flagged the
company in response to the jump in activity. The company has
responded by updating all its OTC Markets required reports.
Management is likely to mitigate the OTC Market’s concerns sooner
or later and see the flag removed which will likely be yet another
impetus fueling a KALY PPS
run.
Management engaged Goldman Small Cap
Research to conduct analyst coverage of the company and file an
initial analyst report: KALY Research
Report
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024